Design and development of leflunomide loaded topical microsponge gel: insights from ex vivo and in vivo inflammatory studies
- 30 June 2025
- journal article
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 30 (6) , 863-874
Abstract
Leflunomide, a frequently used medicament, falls under the category of disease modifying anti-rheumatoid drugs. The tablets are the only product available in the market which may lead to liver toxicity upon long term use. Being a class II drug, there is a need of some novel formulation for minimizing systemic toxicity of drug without compromising its therapeutic potential. Microsponges possess unique characteristics that makes it a versatile drug delivery carrier. Leflunomide loaded Microsponges were prepared with matrix forming polymer (ethyl cellulose) and stabilizer (poly vinyl alcohol) using quasi emulsion solvent diffusion method. Two independent parameters, namely concentrations of polymer and stabilizing agent, were examined using a full 32 factorial design to determine their impact on particle size and % entrapment efficiency. The optimized formulation showed promising result for particle size (48.96µm) and entrapment efficiency (89.45%) with spherical and tiny pores on surface. The optimized gel exhibited sustained release up to 8 h (91.46 ± 3.84%) with satisfactory results of flux and permeability coefficient. The developed formulation has good anti-inflammatory properties in wistar rats and a histopathology investigation on rats' skin verified its skin compatibility. The stability study showed stable formulation up to the period of three months. These findings demonstrated the potential of microsponges to improve the therapeutic potential of poorly soluble leflunomide.Keywords
Funding Information
- Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India (SVRC/ON/2019/19016)
This publication has 38 references indexed in Scilit:
- Recent innovations in topical delivery for management of rheumatoid arthritis: A focus on combination drug deliveryDrug Discovery Today, 2024
- A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritisInternational Journal of Pharmaceutics, 2023
- Hyaluronic acid-coated proglycosomes for topical delivery of tofacitinib in rheumatoid arthritis condition: Formulation design, in vitro, ex vivo characterization, and in vivo efficacy studiesInternational Journal of Biological Macromolecules, 2022
- Formulation and characterization of leflunomide/diclofenac sodium microemulsion base-gel for the transdermal treatment of inflammatory joint diseasesJournal of Drug Delivery Science and Technology, 2021
- Urginea indica attenuated rheumatoid arthritis and inflammatory paw edema in diverse animal models of acute and chronic inflammationJournal of Ethnopharmacology, 2019
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo studyJournal of Advanced Research, 2016
- Leflunomide biodegradable microspheres intended for intra-articular administration: Development, anti-inflammatory activity and histopathological studiesInternational Journal of Pharmaceutics, 2015
- Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activityInternational Journal of Pharmaceutics, 2015
- Temperature and solvent effects in the solubility of some pharmaceutical compounds: Measurements and modelingEuropean Journal of Pharmaceutical Sciences, 2009